About 1.5 million Americans now use cheaper compounded GLP-1 drugs, raising safety and oversight concerns.

The FDA accepted Camurus’s resubmitted application for Oclaiz, a monthly acromegaly treatment, with a decision expected by June 10, 2026.

CelLBxHealth names Peter Collins CEO and new directors, effective Jan. 31, to advance cancer diagnostics.

Futura Medical shares rose 11% after a small trial showed its WSD4000 gel significantly improved female sexual function.

FDA accepts pimicotinib NDA for rare joint tumor, based on positive trial results.

Alamar Biosciences launches a blood test measuring five Alzheimer’s biomarkers for research use.

Boston Scientific to acquire Valencia Technologies for its FDA-approved eCoin device treating overactive bladder.

Taiwan's president announces $90M in subsidies for smart healthcare projects to improve medical efficiency and extend healthy lifespans.

Generic semaglutide may cut drug prices by 65% in Canada by spring 2026 after patent expiry.

A new AI tool predicts how brain tumor patients respond to diet and drugs by modeling real-time tumor metabolism, offering personalized treatment options.